VAXELIS may reduce the number of steps required for vaccine preparation and administration

VAXELIS reduces the need for 2-3 separate injections required with pentavalent vaccines (+hep B or Hib vaccine) in the infant vaccination series1-5

Compare preparation and administration of VAXELIS to:

VAXELISa

1. Shake syringe to obtain suspension.

2. Inspect visually for particulate matter and discoloration prior to administration.

3. Attach a sterile needle to syringe.

4. Administer a single 0.5 mL dose of VAXELIS intramuscularly.

5. Discard unused portion of VAXELIS.

Pediarix®2,6,a

1. Shake syringe to obtain suspension.

2. Inspect visually for particulate matter and discoloration prior to administration.

3. Attach a sterile needle to syringe.

4. Administer a single 0.5 mL dose of Pediarix® intramuscularly.

5. Discard unused portion of Pediarix®.

+ Hiberix®5,6,b-d

1. Cleanse both vial stoppers.

2. Attach a sterile needle to syringe.

3. Withdraw 0.6 mL of saline diluent from the accompanying vial.

4. Transfer 0.6 mL saline diluent into lyophilized vaccine vial.

5. Shake the vial well.

6. Inspect visually for particulate matter and discoloration prior to administration.

7. After reconstitution, withdraw 0.5 mL of reconstituted vaccine.

8. Administer a single 0.5 mL dose of Hiberix® intramuscularly.

9. Discard unused portion of Hiberix®.

This table is provided as a resource by MSP Vaccine Company. It is not intended to be a dosage and administration tool. Steps shown are based on CDC guidance and Prescribing Information. Before administering any vaccine, please read the relevant Prescribing Information. VAXELIS is available in prefilled syringes.

aFully liquid, ready to use.
bReconstitution required before use.
cOther Hib B vaccines may be used in place of Hiberix®.
dSteps may vary as not all monovalent Hib vaccines require reconstitution.

VAXELISa

1. Shake syringe to obtain suspension.

2. Inspect visually for particulate matter and discoloration prior to administration.

3. Attach a sterile needle to syringe.

4. Administer a single 0.5 mL dose of VAXELIS intramuscularly.

5. Discard unused portion of VAXELIS.

Pentacel®1,6,b

1. Cleanse both vial stoppers.

2. Gently shake vial of liquid DTaP-IPV component.

3. Attach a sterile needle to syringe.

4. Withdraw entire liquid component.

5. Inject liquid content into vial of lyophilized ActHIB vaccine component.

6. Gently swirl vial of Pentacel®.

7. Inspect visually for particulate matter or discoloration prior to administration.

8. Withdraw a single 0.5 mL dose of Pentacel®.

9. Administer intramuscularly.

10. Discard unused portion of Pentacel®.

+ Recombivax HB®4,6,a,c

1. Shake prefilled syringe to obtain suspension.

2. Inspect visually for particulate matter and discoloration prior to administration.

3. Attach a sterile needle to syringe.

4. Administer an entire dose of Recombivax HB® intramuscularly.

5. Discard unused portion of Recombivax HB®.

This table is provided as a resource by MSP Vaccine Company. It is not intended to be a dosage and administration tool. Steps shown are based on CDC guidance and Prescribing Information. Before administering any vaccine, please read the relevant Prescribing Information. VAXELIS is available in prefilled syringes.

aFully liquid, ready to use.
bReconstitution required before use.
cOther Hep B vaccines may be used in place of Recombivax HB®.

Order VAXELIS now

Order directly at: VaccineShop.com

For a list of authorized distributors: VaxelisContract.com

References: 1. Pentacel. Prescribing Information. NDC No. 49281-511-05. Sanofi Pasteur; 2022. 2. PEDIARIX. Prescribing Information. GlaxoSmithKIine; 2022. 3. Centers for Disease Control and Prevention. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2023. Accessed September 19, 2023. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf 4. RECOMBIVAX HB. Prescribing Information. Merck & Co., Inc.; 2023. 5. Hiberix. GlaxoSmithKline, Inc.; 2019. Prescribing Information. 6. Centers for Disease Control and Prevention. General best practice guidelines for immunization. Accessed September 19, 2023. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html

What is VAXELIS?

VAXELIS is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b (Hib). VAXELIS is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).

Important Safety Information

  • Do not administer VAXELIS to anyone with a history of severe allergic reaction to a previous dose of VAXELIS, any ingredient of VAXELIS, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis B vaccine, or Hib vaccine.
  • Do not administer VAXELIS to anyone with a history of encephalopathy within 7 days of a pertussis-containing vaccine with no other identifiable cause.
  • Do not administer VAXELIS to anyone with a history of progressive neurologic disorder until a treatment regimen has been established and the condition has stabilized.
  • Carefully consider benefits and risks before administering VAXELIS to persons with a history of: fever ≥40.5°C (≥105°F), hypotonic-hyporesponsive episode (HHE), or persistent, inconsolable crying lasting ≥3 hours within 48 hours after a previous pertussis-containing vaccine; and/or seizures within 3 days after a previous pertussis-containing vaccine.
  • If Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the risk for Guillain-Barré syndrome may be increased following VAXELIS.
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Consider the individual infant’s medical status and potential benefits and possible risks of intramuscular vaccination in deciding when to administer VAXELIS to an infant born prematurely.
  • Vaccination with VAXELIS may not protect all individuals.
  • The solicited adverse reactions 0-5 days following any dose were irritability (≥55%), crying (≥45%), injection site pain (≥44%), somnolence (≥40%), injection site erythema (≥25%), decreased appetite (≥23%), fever ≥38.0°C (≥19%), injection site swelling (≥18%), and vomiting (≥9%).
  • The 3-dose immunization series consists of a 0.5 mL intramuscular injection, administered at 2, 4, and 6 months of age.
  • A 3-dose series of VAXELIS does not constitute a primary immunization series against pertussis; an additional dose of pertussis-containing vaccine is needed to complete the primary series.

Before administering VAXELIS, please read the accompanying Prescribing Information. The Patient Information also is available.

What is VAXELIS®? (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine)

VAXELIS is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b (Hib). VAXELIS is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).

VAXELIS is a vaccine indicated for active immunization to prevent diphtheria, tetanus,

VAXELIS is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b (Hib). VAXELIS is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).

Important Safety Information for VAXELIS® (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine)

  • Do not administer VAXELIS to anyone with a history of severe allergic reaction to a previous dose of VAXELIS, any ingredient of VAXELIS, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis B vaccine, or Hib vaccine.
  • Do not administer VAXELIS to anyone with a history of encephalopathy within 7 days of a pertussis-containing vaccine with no other identifiable cause.
  • Do not administer VAXELIS to anyone with a history of progressive neurologic disorder until a treatment regimen has been established and the condition has stabilized.
  • Carefully consider benefits and risks before administering VAXELIS to persons with a history of: fever ≥40.5°C (≥105°F), hypotonic-hyporesponsive episode (HHE), or persistent, inconsolable crying lasting ≥3 hours within 48 hours after a previous pertussis-containing vaccine; and/or seizures within 3 days after a previous pertussis-containing vaccine.
  • If Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the risk for Guillain-Barré syndrome may be increased following VAXELIS.
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Consider the individual infant’s medical status and potential benefits and possible risks of intramuscular vaccination in deciding when to administer VAXELIS to an infant born prematurely.
  • Vaccination with VAXELIS may not protect all individuals.
  • The solicited adverse reactions 0-5 days following any dose were irritability (≥55%), crying (≥45%), injection site pain (≥44%), somnolence (≥40%), injection site erythema (≥25%), decreased appetite (≥23%), fever ≥38.0°C (≥19%), injection site swelling (≥18%), and vomiting (≥9%).
  • The 3-dose immunization series consists of a 0.5 mL intramuscular injection, administered at 2, 4, and 6 months of age.
  • A 3-dose series of VAXELIS does not constitute a primary immunization series against pertussis; an additional dose of pertussis-containing vaccine is needed to complete the primary series.

Before administering VAXELIS, please read the accompanying Prescribing Information. The Patient Information also is available.

  • Do not administer VAXELIS to anyone with a history of severe allergic reaction to a previous dose of VAXELIS, any ingredient of
  • Do not administer VAXELIS to anyone with a history of severe allergic reaction to a previous dose of VAXELIS, any ingredient of VAXELIS, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis B vaccine, or Hib vaccine.
  • Do not administer VAXELIS to anyone with a history of encephalopathy within 7 days of a pertussis-containing vaccine with no other identifiable cause.